Aveo Announces Preliminary Results of Exploratory Phase II Study Evaluating HGF Inhibitor in First-Line Patients With Advanced Lung Cancer

Aveo Pharmaceuticals announced preliminary data from the exploratory, randomized Phase II study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase inhibitor, to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer, a population with a high prevalence of EGFR sensitizing mutations.
MarketWatch